Physician profile
Henry Cheng
NPI 1669748638
$5,375.64
in general payments reported to CMS, 2019-2025
27 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $1,181 · 2021: $1,496 · 2022: $185 · 2023: $29.22 · 2024: $170 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $842.70 | 2019-2025 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $794.98 | 2019-2022 | |
| Amgen INC. | $550.46 | 2019-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $490.80 | 2019-2025 | |
| Elutia, INC. | $381.19 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $375.26 | 2022-2025 | Amvuttra |
| Amarin Pharma, INC. | $313.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $231.04 | 2019-2022 | |
| Esperion Therapeutics, INC. | $187.88 | 2020-2021 | |
| Medtronic, INC. | $149.93 | 2021 | |
| Merck Sharp & Dohme LLC | $148.75 | 2021-2022 | |
| Pfizer INC. | $147.74 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $117.10 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $116.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $94.98 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.47 | 2019-2022 | |
| Bridgebio Pharma, INC. | $61.80 | 2025 | Attruby |
| Abbott Laboratories | $59.63 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $39.74 | 2021 | |
| Boston Scientific Corporation | $34.06 | 2020-2025 | Watchman Flx |
| Janssen Scientific Affairs, LLC | $32.64 | 2019 | |
| Medtronic Vascular, INC. | $31.14 | 2020 | |
| Lantheus Medical Imaging, INC. | $29.22 | 2023 | Definity |
| Heartflow, INC. | $18.02 | 2025 | |
| Cardiovascular Systems INC. | $16.51 | 2020 | |
| Sobi, INC | $13.98 | 2021 | |
| Novo Nordisk INC | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.